What Are Appropriate End-Points for Helicobacter pylori Eradication in the Treatment of Duodenal Ulcer?

ISSN： 0012-6667

Source： Drugs, Vol.56, Iss.1, 1998-07, pp. : 1-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?

By Akira Babazono Motonobu Miyazaki

PharmacoEconomics, Vol. 22, Iss. 15, 2004-01 ,pp. : 975-983

Adis International

Access to resources Recommend Favorite

Diclofenac: Peptic ulcer disease in a patient with Helicobacter pylori infection?: case report

Reactions Weekly, Vol. 1, Iss. 1298, 2010-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Helicobacter pylori Eradication in Patients with Non-Ulcer Dyspepsia

By Xia H.H-X. Talley N.J.

Drugs, Vol. 58, Iss. 5, 1999-11 ,pp. : 785-792

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Helicobacter pylori Eradication Therapies in Patients with Duodenal Ulcer: An Analysis of Triple Therapy Versus Two Dual Therapy Alternatives

By Tennvall G.R.

PharmacoEconomics, Vol. 16, Iss. 3, 1999-09 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

H. pylori eradication justified in nonulcer dyspepsia?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 281, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite